Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · IEX Real-Time Price · USD
0.753
-0.067 (-8.17%)
May 7, 2024, 3:06 PM EDT - Market open
Sol-Gel Technologies Revenue
In the year 2023, Sol-Gel Technologies had annual revenue of $1.55M, a decrease of -59.98%. Revenue in the quarter ending December 31, 2023 was $447.00K with 347.00% year-over-year growth.
Revenue (ttm)
$1.55M
Revenue Growth
-59.98%
P/S Ratio
14.50
Revenue / Employee
$43,167
Employees
36
Market Cap
21.17M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
| Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
| Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
| Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
| Dec 31, 2019 | 22.90M | 22.78M | 17,655.04% |
| Dec 31, 2018 | 129.00K | -45.00K | -25.86% |
| Dec 31, 2017 | 174.00K | - | - |
| Dec 31, 2016 | 0 | - | - |
| Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ATI Physical Therapy | 713.56M |
| Cue Health | 70.94M |
| DermTech | 15.30M |
| Nephros | 14.24M |
| TherapeuticsMD | 1.30M |
| Aptorum Group | 431.38K |
SLGL News
- 5 weeks ago - Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream - GlobeNewsWire
- 7 weeks ago - Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments - GlobeNewsWire
- 5 months ago - Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study - GlobeNewsWire
- 5 months ago - Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 - GlobeNewsWire
- 6 months ago - Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - GlobeNewsWire
- 9 months ago - Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada - Business Wire